URGN Stock Hub: ZUSDURI, UGN-103 and IntraGel

01Executive Summary

H1 revenue was $123.4M, including Q2 $72.5M and ZUSDURI $50.4M. Q2 operating income of $0.111M did not translate into net profit: net loss was $14.4M after financing, interest and tax. June liquid assets were about $108M, liabilities $385M and shareholders’ deficit $132.4M. UroGen has used equity, secured debt and revenue financing; shareholder dilution has occurred. UGN-103 was submitted August 17; FDA acceptance and a PDUFA date remain unconfirmed. Sustained commercial cash generation is the key test.

SEC · Q2 2026

02What The Company Actually Is Today

UroGen Pharma is a commercial-stage biopharmaceutical company focused on urothelial and specialty cancers. Its distinguishing technology is a reverse-thermal hydrogel that is liquid when cold and becomes a gel at body temperature, which allows a drug to be instilled into the urinary tract and stay in contact with tissue instead of being flushed away. That is the whole platform, and both approved products use it.

Trailing twelve month revenue is US$188.7 million, up 100.3%, against a trailing net loss of US$(97.6) million. The company is not yet profitable, but the gap between those two numbers is closing at a rate that very few names at this size can show.

The commercial model is worth understanding because it is unusual. These are physician-administered products delivered in a urology office, which means the sales effort is a specialty field force calling on a defined and countable set of practices, and reimbursement runs through buy-and-bill rather than pharmacy benefit. That is why selling, general and administrative expense of US$48.4 million in the quarter is nearly three times research and development at US$17.3 million.

September 4 awards cover up to 117,100 shares for 19 new employees, vesting over three years, not immediate issuance of all shares. Mark Schoenberg’s August 24 Form 4 reports a sale of 60,677 shares on August 20 at weighted $47.05; this is separate from employee RSU grants. No motive is inferred.

IR · grants · SEC · Form 4

03ZUSDURI: The Launch That Changed The Scale

ZUSDURI is the reason the revenue line looks the way it does. It produced US$50.4 million in the second quarter of 2026, a 73% increase over the first quarter, and it has overtaken JELMYTO to become the larger of the two products in barely more than a year of selling.

The account-level detail underneath that number is published. At June 30, 2026 the company reported 1,444 activated sites of care, 452 unique prescribers and 204 repeat prescribers, the last representing about 45% of total prescribers against 40% in the first quarter. The repeat share is the most informative of the three, because a product that removes a procedure either gets used again by the same urologist or it does not.

On durability, updated ENVISION data reported with the quarter showed a 36-month duration of response of 64.5% (95% CI: 54.6, 72.8) by Kaplan-Meier estimate among the 79.6% of patients who reached a complete response at three months, at a median follow-up of 35.5 months, with the median duration of response not reached. That result was achieved without maintenance therapy.

The clinical proposition explains why uptake has been fast. Low-grade intermediate-risk non-muscle invasive bladder cancer is conventionally managed by repeated surgical resection under anaesthesia, a procedure patients undergo again and again as the disease recurs. A treatment that can be instilled in a urology office and reduce that cycle changes the experience for the patient and the economics for the practice at the same time. When a launch curve is this steep, the usual explanation is that the product removes a procedure rather than adding a drug.

Two cautions belong next to that number. A 73% sequential increase cannot repeat indefinitely; launch curves flatten as the prevalent pool of already-diagnosed patients is treated and the business converts to incident demand. And a buy-and-bill product carries reimbursement risk that a pharmacy product does not: the practice fronts the cost and is repaid, so any change in coding, coverage or payment rate feeds straight into ordering behaviour.

04JELMYTO: The Base That Is Now The Smaller Half

JELMYTO treats low-grade upper tract urothelial cancer, a rarer disease than bladder cancer, where the alternative is often removal of the kidney and ureter. It generated US$22.0 million in the second quarter, against US$24.2 million in the second quarter of 2025. That is a decline of roughly 9% year on year, and it is the most easily missed number in the release, because the growth of the company as a whole conceals it completely.

Two things are true at once. The company states that it continues to add new users and remains on track to deliver within its full-year guidance range, and the base product still shrank in the quarter it has just reported. Whether that was timing or the start of a plateau is a question for the third-quarter print rather than one that can be settled now.

Management guides full-year JELMYTO revenue to US$97-101 million, against US$94 million in 2025. That is growth of 3% to 7% for the year as a whole, from a product that declined year on year in the quarter just reported. It should be read as what it is: a mature product in a small indication, no longer the story, and now carrying a dated end point.

The guidance is nonetheless useful, because it isolates the rest. If JELMYTO lands in the middle of its guided range at about US$99 million for the year, and the first half of the company’s total revenue was US$123.4 million, then essentially all the incremental revenue growth in 2026 has to come from ZUSDURI. The company has, in effect, published a single-variable model of its own year.

The 2030 Generic Date

Alongside the second-quarter release the company confirmed a settlement and license agreement with Teva, resolving the patent litigation UroGen brought after Teva filed an abbreviated new drug application for a generic version of JELMYTO. Under the agreement Teva holds a non-exclusive licence to sell that generic from September 15, 2030, if the FDA approves it, subject to the limited circumstances customarily included in agreements of this type.

The date changes nothing in 2026 and nothing in the guidance above. What it does is put an end point on the JELMYTO franchise that can be written in a calendar, which is more than most products of this age offer in either direction. The litigation and the settlement are covered separately in the UroGen and Teva report.

05The Q2 2026 Numbers In Order

The figures below come from the second quarter results announced on August 5, 2026.

Three observations follow. First, revenue nearly tripled year on year in the half, from US$44.5 million to US$123.4 million, which is the kind of change that usually accompanies a first approval rather than a second year of selling. Second, the operating line has already crossed over: operating income was US$0.111 million in the quarter, against an operating loss of US$(41.448) million a year earlier, and the remaining US$(14.4) million net loss is created beneath it by financing costs and tax. Third, the balance sheet moved the other way: liabilities exceed assets by US$132.4 million, and the deficit widened from US$(124.3) million at March 31.

H1 operating cash use was $78.322M despite Q2 operating income of $0.111M: receivables, inventory and timing matter. Q2 net loss was $14.351M after financing, interest and tax. June liquid assets around $108M exclude restricted cash; the second $50M debt tranche is availability, not cash already received. SEC projects resources beyond one year from the August 5 filing, dependent on commercial cash flows.

SEC · Q2

06Guidance And What It Implies For The Second Half

What the company has not guided is total revenue, and that omission is itself information. By guiding JELMYTO precisely and leaving ZUSDURI open, management has declined to put a number on the variable that matters most while the launch curve is still steep. That is a defensible choice at this stage of a launch, and it also means the market is modelling the largest line without a company anchor.

The operating expense guidance is the more testable figure, and it moved. The company raised the range in this release and said why: accelerated investment in peer-to-peer promotional education and patient awareness behind ZUSDURI, start-up activity for the UGN-103 trial in high-risk NMIBC, and development work on UGN-501. That is a company spending into a launch that is working rather than one defending a cost line, and it should be read that way. The consequence is that the path to sustained profitability is deliberately being pushed out in exchange for a larger franchise.

07The Shareholders’ Deficit

June assets of $252.6M and liabilities of $385M imply a $132.4M shareholders’ deficit. This reflects accumulated losses and the financing mix, including equity issuance. A negative book value is not by itself insolvency. Management projects resources beyond one year from August 5 using commercial cash-flow assumptions; weaker receipts could require financing or spending reductions. Profits, equity issuance and other balance-sheet changes can affect the deficit.

SEC · Q2 2026

08How The Debt Actually Works

Pharmakon: $200M drawn, $188.7M carrying value June 30; fixed 8.25%, five-year maturity from February 26, 2026. It refinanced $125M principal; the additional $50M tranche available until June 30, 2027 is undrawn, not cash. RTW prepaid forward carrying value: $125.1M non-current plus $7.7M current. Contractual annual sales tiers up to $200M / $200–300M / above $300M apply separately: JELMYTO/UGN-104 9.5% / 3% / 1%, with the first tier currently 13%; ZUSDURI/UGN-103 2.5% / 1% / 0.5%. Payments stop at $300M cumulative; $55.1M was paid or payable by June. These contractual thresholds differ from the accounting liability. June common shares were 48,869,530 and pre-funded warrants 1,615,522; the latter are disclosed instruments, not inferred from EPS averages. The 2024 offering raised $107.5M gross plus $16.1M through the option. Q4 2025 ATM sales of 1,370,962 shares raised $31.8M net; remaining ATM capacity June 30 was $42.4M, which is potential financing, not cash.

SEC · Q2 2026

09Pipeline: UGN-103, UGN-104 And UGN-501

The NDA went in on August 17, 2026, inside the guided window. The submission is supported by the Phase 3 UTOPIA trial, a single-arm study in 99 patients who received 75 mg of UGN-103 once weekly for six weeks: a three-month complete response rate of 77.8% (95% CI: 68.3, 85.5) and a six-month duration of response of 94.5% (95% CI: 86.1, 97.9) by Kaplan-Meier estimate. The company states both figures are consistent with the pivotal ENVISION trial of ZUSDURI, and that no formal cross-trial comparison was performed. UGN-103 comes from a January 2024 licensing and supply agreement with medac, and the intellectual property covering it is expected to run into July 2044.

What happens next is procedural rather than clinical. The FDA has to accept the filing before a review clock and a PDUFA date exist, and the company has not announced an acceptance. Until then there is no date to trade around, only a submission that has been made.

UGN-103 is the item that matters in the next few months, and it is a different kind of catalyst from the usual biotech binary. It is a next-generation formulation in an indication where the company already sells an approved product, so approval would extend and defend a franchise rather than create one. That makes the risk profile asymmetric in an unusual direction: a delay is a nuisance rather than a catastrophe, because ZUSDURI keeps selling either way.

UGN-104 and UGN-501 are further out and should be treated as optionality rather than as drivers. Neither produces data that changes 2026.

IntraGel: a second delivery platform, taken as an option rather than bought

On August 18, 2026 UroGen’s US subsidiary signed an Option and Research License Agreement with IntraGel Therapeutics, an Israeli company, and disclosed it in an 8-K filed on August 20. The structure has three parts: an exclusive option on a worldwide licence to TumoCure, IntraGel’s investigational cisplatin therapy formulated with its SRGel platform, for advanced head and neck cancer; options on worldwide licences for up to three further oncology products combining SRGel with compounds UroGen will designate; and a non-exclusive research licence to evaluate the platform itself. Alongside it, a Securities Purchase Agreement under which UroGen will invest up to US$7 million in IntraGel equity.

What SRGel is. A biodegradable, water-free and solvent-free polymer matrix based on fatty acids, injected directly into a tumour, designed to release a drug locally over months while keeping systemic exposure low. TumoCure is cisplatin in that matrix, given as a single intratumoral injection, aimed at patients with locally advanced inoperable head and neck cancer who cannot take systemic cisplatin-based chemoradiation. IntraGel is pursuing the 505(b)(2) pathway and describes the candidate as Phase 2-ready. The clinical evidence so far is eight patients: data presented at ASCO 2026 showed the therapy was generally well tolerated with low systemic cisplatin exposure and early signs of anti-tumour activity in a heavily pretreated population.

August 18 agreements, announced August 20: UroGen obtained a non-exclusive research license to SRGel and options for exclusive worldwide licenses covering TumoCure and up to three additional oncology products. TumoCure’s option follows IntraGel Phase 2 completion; eight Phase 1b patients provide only early evidence. Up to $7M is an investment commitment into IntraGel equity, not cash raised by UroGen, a completed acquisition or proof all options were exercised.

SEC · IntraGel

UTOPIA NCT06331299: 99 actual participants; January 15 registry remains active, not recruiting, with primary completion September 11, 2025 and estimated overall completion September 2026. The latter is not a new promised readout or FDA action date. The August 17 submission reports 77.8% three-month CR and 94.5% six-month KM DOR; cross-trial similarity to ENVISION does not prove superiority.

IR · UGN-103

10Patent Position

In the second-quarter release the company reported a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering methods of treating recurrent low-grade intermediate-risk non-muscle invasive bladder cancer without transurethral resection of bladder tumour. Once the patent issues, protection is expected to run into July 2044, and it is stated to cover both ZUSDURI and UGN-103.

The conditional matters here. An allowance is not an issued patent, and the protection described does not exist until the patent issues.

For a company whose entire commercial base sits in that indication, the length of that protection is a material fact rather than a footnote. It does not by itself exclude competitors, because a competitor can design around a formulation patent or arrive with a different mechanism, but it does define the period over which the current franchise can be defended without a new approval.

11Analysts And Market Data

Finviz retrieval September 6; provider market value $2,155.12M differs slightly through timing/rounding. Basic shares exclude pre-funded warrants and incentive awards. Aggregates overlap and are not an exclusive ownership partition. Old analyst targets are dated opinions, not guaranteed upside.

12The Target Price Problem

The historical analyst table dated May–July and vendor snapshots from August are not current coverage. At the September 4 Marketstack close of $44.09, a $45 target is 2.06% above the price and $37.13 is 15.79% below. Prior conflicting aggregate targets should not be treated as a verified current consensus. No target is a valuation floor or a forecast guaranteed by commercial growth.

SEC · Q2 2026

13Retail Sentiment

StockTwits September 7: canonical sentiment 33/100 bearish; activity 34/100 low; 2,280 watchers. The tagged subset is 100% bullish but is not the canonical normalized score. Neither proves commercial demand or predicts FDA review.

14What Bulls See

A launch that is demonstrably working. Revenue of US$123.4 million in the first half against US$44.5 million a year earlier, with ZUSDURI up 73% in a single quarter.

ZUSDURI has already overtaken JELMYTO. The newer product passed the older one inside roughly a year of selling, which is fast for a physician-administered therapy.

The operating line has already crossed over. Operating income was US$0.111 million in the quarter, against an operating loss of US$(41.4) million a year earlier. What remains of the US$(14.4) million net loss is created below the operating line, by financing costs and tax.

Prescribers are coming back. Repeat prescribers reached about 45% of the total, from 40% a quarter earlier, across 452 unique prescribers and 1,444 activated sites of care.

Financing flexibility includes debt and an ATM, with real dilution risk; historical equity issuance is documented in section 08.

A defensible franchise. A patent allowance stated to run to July 2044 in the core indication, in a market where the alternative to the drug is repeated surgery.

A near-term regulatory step with low downside. The UGN-103 NDA, submitted on August 17, 2026, extends an existing franchise rather than creating one, so even a slow review does not stop the revenue.

15What Bears See

Key risks are a $132.4M book deficit, $200M secured principal, contractual revenue payments, $78.322M H1 operating cash use and further dilution. ZUSDURI drives growth while Q2 JELMYTO revenue fell year over year. Watch reimbursement, cash collection, spending versus full-year guidance and FDA acceptance of UGN-103. Historical targets do not establish downside protection.

SEC · Q2 2026

16Scenario Framework

Constructive scenario: further ZUSDURI adoption, better cash conversion and acceptance of UGN-103. Difficult scenario: slower sales, reimbursement friction, financing needs or regulatory delays. An intermediate scenario combines continued sales growth with persistent net losses. The $260–270M OpEx guidance is for full-year 2026, not one quarter. These are qualitative possibilities with no assigned probabilities.

SEC · Q2 2026

17Bottom Line

UroGen has done the hard part. Two approved products, a launch that took the newer one past the older one in about a year, revenue that nearly tripled year on year in the half, and a quarterly loss down to US$14.4 million. Most companies covered in this series would take that outcome.

What is verified: US$72.456 million of Q2 revenue, of which US$50.4 million from ZUSDURI, up 73% sequentially, and US$22.0 million from JELMYTO against US$24.2 million a year earlier; US$123.415 million in the first half against US$44.469 million a year earlier; operating income of US$0.111 million against an operating loss of US$(41.448) million in Q2 2025; a Q2 net loss of US$(14.351) million, or US$(0.28) per share, after US$5.629 million of income tax expense; US$107.976 million of cash, equivalents and marketable securities at June 30, 2026, of which US$79.133 million was cash and equivalents; total liabilities of US$384.986 million against assets of US$252.590 million, a shareholders’ deficit of US$(132.396) million and an accumulated deficit of US$(997.641) million; a Pharmakon facility of up to US$250 million with a US$200 million first tranche carried at US$188.7 million at a fixed 8.25%, and a prepaid forward to RTW of US$125.1 million non-current plus US$7.7 million current; 2026 guidance of US$97-101 million for JELMYTO and a raised US$260-270 million of operating expense; and a UGN-103 NDA submitted to the FDA on August 17, 2026.

What is not verified: the full covenant detail on the term loan, total 2026 revenue, which the company has not guided, whether the FDA accepts the UGN-103 filing and on what review clock, and whether the second-quarter decline in JELMYTO was timing or the beginning of a plateau.

The question this hub cannot answer, and no commentary can, is the one that follows from all of it: the business is working, and the equity sits behind a term loan and a sold revenue interest. The next print is where those two facts either start converging or keep pulling apart.

Confirmed conference times: Wells Fargo September 9 15:00 EDT; Cantor September 10 14:10 EDT; H.C. Wainwright September 15 09:00 EDT (Italy +6 hours). These are investor presentations, not scheduled NDA decisions.

IR · events